Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
GSK
Biotech
GSK loses hope for CD226 cancer therapies, dropping ph. 2 assets
GSK once dreamed of harnessing the CD226 axis to create a new generation of blockbuster cancer drugs.
James Waldron
Oct 29, 2025 6:29am
GSK pens $750M deal for COPD-focused oligonucleotide in phase 1
Oct 28, 2025 6:45am
GSK pens $357M pact with French biotech for prostate cancer ADC
Oct 27, 2025 4:07am
Alector halves staff after GSK-partnered antibody fails in ph. 3
Oct 22, 2025 11:23am
GSK unveils pivotal data on oral antibiotic ahead of FDA filing
Oct 21, 2025 10:55am
ESMO: The ADC 'rollercoaster' rides on with next-gen meds
Oct 21, 2025 3:00am
